Investors Press Release/News Aucta Pharmaceuticals, Inc. ("Aucta Pharmaceuticals") launches MOTPOLY XR™ (lacosamide) extended-release capsules C-V, the first, and only once-daily formulation of lacosamide Aucta announced FDA approval of a generic version of Trileptal®(oxcarbazepine) oral suspension Aucta announces FDA approval of a generic version of Perforomist® (Formoterol Fumarate) Inhalation Solution Aucta Pharmaceuticals AnnouncesLicensing of Vigabatrin for Oral Solution in China Aucta Pharmaceuticals Announces Licensing of Lamotrigine New Drug Application Aucta Receives its First Product Approval and Launches Vigabatrin for Oral Solution Under the Brand Name Vigadrone™
